Windtree Therapeutics, Inc. (WINT)
Largest Insider Buys in Sector
WINT Stock Price History Chart
WINT Stock Performance
About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress …
Insider Activity of Windtree Therapeutics, Inc.
Over the last 12 months, insiders at Windtree Therapeutics, Inc. have bought $4,942 and sold $0 worth of Windtree Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Windtree Therapeutics, Inc. have bought $1.13M and sold $1.98M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Fraser Craig (President and CEO) — $4,942.
The last purchase of 5,431 shares for transaction amount of $4,942 was made by Fraser Craig (President and CEO) on 2024‑10‑08.
List of Insider Buy and Sell Transactions, Windtree Therapeutics, Inc.
| 2024-10-08 | President and CEO | 5,431 0.1036% | $0.91 | $4,942 | -37.58% | |||
| 2023-09-27 | President and CEO | 2,500 0.0535% | $1.02 | $2,550 | -61.74% | |||
| 2023-09-26 | President and CEO | 2,500 0.0472% | $0.90 | $2,250 | -56.72% | |||
| 2023-04-26 | President and CEO | 1,497 0.0556% | $1.77 | $2,650 | -42.28% | |||
| 2023-04-25 | President and CEO | 1,315 0.0521% | $1.89 | $2,485 | -45.16% | |||
| 2022-07-27 | President and CEO | 2,500 0.0199% | $0.38 | $950 | -55.94% | |||
| 2022-07-26 | President and CEO | 2,500 0.0196% | $0.37 | $935 | -55.29% | |||
| 2022-07-26 | SVP & CFO | 3,000 0.0231% | $0.37 | $1,100 | -55.29% | |||
| 2022-06-30 | President and CEO | 4,500 0.0404% | $0.43 | $1,926 | -59.23% | |||
| 2022-06-29 | President and CEO | 7,000 0.061% | $0.42 | $2,908 | -59.21% | |||
| 2022-03-16 | President and CEO | 2,000 0.0411% | $0.98 | $1,960 | -62.15% | |||
| 2022-03-15 | President and CEO | 3,000 0.0617% | $0.98 | $2,940 | -61.28% | |||
| 2022-03-15 | SVP, Chief Medical Officer | 5,000 0.1048% | $1.00 | $4,999 | -61.28% | |||
| 2021-12-30 | Sale | 10 percent owner | 1.24M 41.5705% | $1.60 | $1.98M | -69.87% | ||
| 2021-12-30 | 10 percent owner | 1.24M 41.5705% | $1.60 | $1.98M | -69.87% | |||
| 2021-11-19 | President and CEO | 930 0.0312% | $1.60 | $1,488 | -66.92% | |||
| 2021-11-18 | President and CEO | 930 0.0314% | $1.61 | $1,497 | -67.40% | |||
| 2021-10-22 | President and CEO | 3,000 0.1195% | $1.90 | $5,700 | -58.51% | |||
| 2021-10-19 | director | 50,000 1.9948% | $1.90 | $95,135 | -52.33% | |||
| 2021-10-19 | President and CEO | 3,000 0.1201% | $1.91 | $5,730 | -52.33% |
Insider Historical Profitability
| Fraser Craig | President and CEO | 8638 0.0961% | $0.32 | 31 | 0 | <0.0001% |
| ESTEVE ANTONIO PHD | director | 3201574 35.6133% | $0.32 | 5 | 0 | |
| Lee's Pharmaceutical Holdings Ltd | 10 percent owner | 2853271 31.7389% | $0.32 | 1 | 0 | |
| Center Laboratories, Inc. | 10 percent owner | 1239088 13.7832% | $0.32 | 2 | 0 | |
| CAPETOLA ROBERT J | President/CEO | 446025 4.9614% | $0.32 | 9 | 0 |